Navigation Links
Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
Date:7/17/2014

Splice-Switching Oligonucleotide Therapeutics Is Promising New Method for Editing Gene Transcripts

New Rochelle, NY, July 17, 2014In splice-switching, an innovative therapeutic approach, targeted oligonucleotide drugs alter the editing of a gene transcript to produce the desired form of a protein. Developments in this rapidly advancing field have already led to promising treatments for such diseases as Duchenne Muscular Dystrophy and spinal muscular atrophy, as described in an article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Human Gene Therapy website.

In "Development of Therapeutic Splice-Switching Oligonucleotides," Petra Disterer and coauthors from University College London, University of London, and Queen Mary University of London, UK, and Medical University of Warsaw, Poland, present an overview of the many possible therapeutic applications for splice-switching oligonucleotides. The authors discuss the design and chemical modification of these novel compounds to increase their stability and effectiveness, and emphasize the need to develop efficient solutions on a case by case basis.

"This is an emerging therapeutic area with promising clinical results," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>

Contact: Kathryn Ruehle
kruehle@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Industry group release testing recommendations for oligonucleotide-based therapeutics
2. Oligonucleotide Delivery: Biology, Engineering and Development Conference
3. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
4. Next-generation glaucoma therapeutics hold considerable promise
5. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
6. Emerging class of therapeutics represents a coming wave for developers and manufacturers
7. Natura Therapeutics product shown to improve decision making skills in older adults
8. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
9. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
10. Drug development venture links translational research, business to launch new therapeutics
11. UCLA scientists develop new therapeutics that could accelerate wound healing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... leveraged recent innovations in biotechnology to help treat hormonal and stress related hair ... Nutrafol® has captured the hearts of key opinion leaders in the medical and ...
(Date:5/3/2016)... ... 2016 , ... Leading CEOs from biotech, pharmaceutical, and healthcare ... 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference is ... access to key decision makers who influence deal making and investment. Attendees gain ...
(Date:5/3/2016)... - And Other Rising Companies ... Those Competitor Biologics  - Biosimilar Drug Producers ... ,  Who are the most important and ... their sales potentials? Discover, in our updated survey, organisations, ... and revenue forecasting. Visiongain,s new ...
(Date:5/2/2016)... 2, 2016 Q BioMed Inc. ... partner Mannin Research Inc. will be attending the Association ... place from May 1-5, 2016 in Seattle ... with its vendors and research partners. The meeting provides ... and other collaborative opportunities for the MAN-01 program for ...
Breaking Biology Technology: